Literature DB >> 7441495

Prednisolone clearance at steady state in dogs.

F J Frey, B M Frey, A Greither, L Z Benet.   

Abstract

The purposes of this study were: 1) to determine in dogs under steady-state conditions whether prednisolone clearance increases with increasing dose as has been suggested from results obtained under nonsteady-state conditions in man and 2) to determine whether the prednisolone to prednisone conversion, apparently resulting from 11 beta-hydroxydehydrogenase, is saturable. Six dogs were given four different zero-order infusions of prednisolone resulting in steady-state levels from 23 to 5884 ng/ml.Prednisone, total and free prednisolone levels were assessed by high-pressure liquid chromatography and equilibrium dialysis. Total and unbound prednisolone clearances were calculated by dividing the infusion rate by the total or unbound prednisolone concentration at steady state. Both total and unbound prednisolone clearance exhibited a slight tendency to decrease (P < .05) with increasing prednisolone steady-state levels. The conversion of prednisolone to prednisone, defined by the prednisolone/prednisone ratio, exhibited saturable characteristics which, when data for all dogs was fitted to a Michaelis-Menten type equation (r2 = 0.938), gave a Km of 658 ng/ml, i.e., total prednisolone concentration at half-maximal saturation.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7441495

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  21 in total

1.  Nonlinear pharmacokinetics and interconversion of prednisolone and prednisone in rats.

Authors:  M L Huang; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1990-10

Review 2.  Clinical pharmacokinetics of prednisone and prednisolone.

Authors:  B M Frey; F J Frey
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

3.  Pharmacokinetics of fluocortolone in man.

Authors:  U F Legler
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Interaction of mixed micelles formed from glycocholic acid and lecithin with the protein binding of various drugs.

Authors:  T W Guentert; S Oie; L Paalzow; B M Frey; R Brandt; L J Aarons; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1987-05       Impact factor: 4.335

5.  The dose-dependent systemic availability of prednisone: one reason for the reduced biological effect of alternate-day prednisone.

Authors:  F J Frey; M K Rüegsegger; B M Frey
Journal:  Br J Clin Pharmacol       Date:  1986-02       Impact factor: 4.335

6.  Physiologically Based Pharmacokinetic Modeling Involving Nonlinear Plasma and Tissue Binding: Application to Prednisolone and Prednisone in Rats.

Authors:  Xiaonan Li; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  J Pharmacol Exp Ther       Date:  2020-09-03       Impact factor: 4.030

7.  Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin.

Authors:  K H Lee; J G Shin; W S Chong; S Kim; J S Lee; I J Jang; S G Shin
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 8.  Protein binding displacement interactions and their clinical importance.

Authors:  J C McElnay; P F D'Arcy
Journal:  Drugs       Date:  1983-05       Impact factor: 9.546

9.  Assessment of the impact of dosing time on the pharmacokinetics/pharmacodynamics of prednisolone.

Authors:  Jian Xu; Julia Winkler; Sreedharan Nair Sabarinath; Hartmut Derendorf
Journal:  AAPS J       Date:  2008-06-25       Impact factor: 4.009

10.  The macromolecular binding of prednisone in plasma of healthy volunteers including pregnant women and oral contraceptive users.

Authors:  L E Gustavson; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1985-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.